Roivant Sciences (NASDAQ:ROIV) PT Raised to $18.00

Roivant Sciences (NASDAQ:ROIVFree Report) had its target price lifted by HC Wainwright from $17.00 to $18.00 in a report released on Wednesday morning, Benzinga reports. They currently have a buy rating on the stock.

A number of other research firms also recently weighed in on ROIV. Bank of America boosted their target price on Roivant Sciences from $11.00 to $12.00 and gave the stock a neutral rating in a research report on Tuesday, January 2nd. TheStreet raised Roivant Sciences from a d rating to a c+ rating in a research note on Tuesday, February 13th. Deutsche Bank Aktiengesellschaft assumed coverage on Roivant Sciences in a research note on Tuesday, December 12th. They set a buy rating and a $14.00 price objective for the company. Piper Sandler assumed coverage on Roivant Sciences in a research note on Friday, January 5th. They set an overweight rating and a $20.00 price objective for the company. Finally, Truist Financial reaffirmed a buy rating and set a $23.00 price objective on shares of Roivant Sciences in a research note on Monday, March 25th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average target price of $16.90.

Get Our Latest Report on Roivant Sciences

Roivant Sciences Trading Up 5.4 %

Shares of ROIV opened at $11.51 on Wednesday. The company has a market cap of $9.28 billion, a price-to-earnings ratio of 2.21 and a beta of 1.34. Roivant Sciences has a 52-week low of $6.97 and a 52-week high of $13.24. The company has a debt-to-equity ratio of 0.06, a quick ratio of 27.79 and a current ratio of 27.79. The stock has a fifty day moving average price of $10.78 and a two-hundred day moving average price of $10.36.

Roivant Sciences (NASDAQ:ROIVGet Free Report) last released its earnings results on Tuesday, February 13th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.07. The company had revenue of $37.14 million during the quarter, compared to the consensus estimate of $30.72 million. Roivant Sciences had a negative return on equity of 33.38% and a net margin of 3,624.14%. Analysts predict that Roivant Sciences will post -1.36 EPS for the current fiscal year.

Insider Buying and Selling at Roivant Sciences

In other news, COO Eric Venker sold 96,950 shares of the business’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $10.92, for a total value of $1,058,694.00. Following the sale, the chief operating officer now directly owns 532,207 shares in the company, valued at $5,811,700.44. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 4.60% of the company’s stock.

Institutional Trading of Roivant Sciences

Institutional investors have recently modified their holdings of the company. Dagco Inc. bought a new stake in shares of Roivant Sciences in the fourth quarter valued at about $27,000. Citigroup Inc. lifted its holdings in shares of Roivant Sciences by 1,803.6% in the first quarter. Citigroup Inc. now owns 5,749 shares of the company’s stock valued at $28,000 after purchasing an additional 5,447 shares in the last quarter. Royal Bank of Canada raised its holdings in Roivant Sciences by 60,550.0% during the first quarter. Royal Bank of Canada now owns 6,065 shares of the company’s stock worth $30,000 after acquiring an additional 6,055 shares in the last quarter. FNY Investment Advisers LLC bought a new stake in Roivant Sciences during the fourth quarter worth about $33,000. Finally, Headlands Technologies LLC bought a new stake in Roivant Sciences during the fourth quarter worth about $36,000. 64.76% of the stock is currently owned by institutional investors.

Roivant Sciences Company Profile

(Get Free Report)

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

Featured Articles

Analyst Recommendations for Roivant Sciences (NASDAQ:ROIV)

Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.